0
Clinical Investigations: ASTHMA |

Health-Related Quality of Life in Moderate Asthma*: 400 μg Hydrofluoroalkane Beclomethasone Dipropionate vs 800 μg Chlorofluorocarbon Beclomethasone Dipropionate

Elizabeth F. Juniper, MCSP, MSc; A. Sonia Buist, MD; The Study Group; The Study Group
Author and Funding Information

Affiliations: *From the Department of Clinical Epidemiology and Biostatistics (Prof. Juniper), McMaster University Medical Centre, Ontario, Canada; and the Department of Pulmonary and Critical Care Medicine (Dr. Buist), Oregon Health Sciences University Hospital, Portland, OR. ,  A complete list of participants is located in the Appendix.

Correspondence to: Elizabeth F. Juniper, MCSP, MSc, Clinical Epidemiology and Biostatistics, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario L8S 3Z5, Canada


Affiliations: *From the Department of Clinical Epidemiology and Biostatistics (Prof. Juniper), McMaster University Medical Centre, Ontario, Canada; and the Department of Pulmonary and Critical Care Medicine (Dr. Buist), Oregon Health Sciences University Hospital, Portland, OR. ,  A complete list of participants is located in the Appendix.


Chest. 1999;116(5):1297-1303. doi:10.1378/chest.116.5.1297
Text Size: A A A
Published online

Objective: To compare the effect of hydrofluoroalkane-134a (HFA) beclomethasone dipropionate (BDP; 400μ g/d) with that of chlorofluorocarbon (CFC) BDP (800 μg/d) on asthma health-related quality of life in a 12-week, parallel-group, multicenter study.

Background: HFA-BDP is a new CFC-free preparation of BDP, which was developed as a result of CFCs being phased out from metered dose inhalers.

Methods: Following 7 to 12 days of prednisone, 30 mg/d, 347 adults with moderate asthma were randomized to receive either 400μ g/d HFA-BDP, 800 μg/d CFC-BDP, or HFA placebo for 12 weeks (all other oral and inhaled steroids were withdrawn). Patients completed the Asthma Quality of Life Questionnaire (AQLQ), and clinical asthma status was measured at the end of a run-in period, at randomization (after oral steroid treatment), and at the end of the study treatment.

Results: Sixty-one patients withdrew, 43 due to worsening asthma (33 placebo; 5 HFA-BDP; 5 CFC-BDP). There was a deterioration in the AQLQ score (− 0.81) in the placebo group, and the difference between this and the stability observed in both the HFA-BDP group (+ 0.13) and the CFC-BDP group (− 0.03) was statistically significant (p ≤ 0.003). The difference between the two active treatments was not significant (p = 0.290). The calculated number of patients who needed to be treated in order to see a benefit in one patient (with the placebo as the standard treatment) was 2.4 for HFA-BDP and 3.0 for CFC-BDP. Only weak to moderate correlations were observed between changes in AQLQ scores and between asthma clinical status measures.

Conclusion: HFA-BDP (400μ g/d) was as effective as CFC-BDP (800 μg/d) in sustaining improvements in asthma quality of life following withdrawal of 7 to 12 days of prednisone treatment in moderate asthma.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543